MED-EL CI System
Med-El Corp. · Decision date Nov 26, 2025
What did the FDA approve?
FDA records P000025/S134 as a supplement to PMA P000025, with the supplement type “Panel Track”. The recorded decision is approval, dated Nov 26, 2025.
FDA approval order statement
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the MED-EL CI System for expanding the indication for use. The expanded device indications include children with bilateral hearing loss who meet the following criteria:The MED-EL Cochlear Implant System is intended to evoke auditory sensations via electrical stimulation of the auditory pathways for individuals with debilitating sensorineural hearing loss (SNHL) who obtain limited benefit from acoustic amplification in the ear(s) to be implanted and is indicated for the following pediatric populations: Children aged 7 months to 17 years, 11 months must demonstrate a bilateral SNHL as follows. Children implanted at 7-11 months of age should demonstrate a profound SNHL, defined by a 3-frequency pure-tone average (PTA3) of ?90 dB HL at 500, 1000, and 2000 Hz. Children implanted at 12-71 months of age should demonstrate a moderately-severe to profound SNHL in the low frequencies, defined by a PTA3 ? 55dB HL at 500, 1000, and 2000 Hz and a severe to profound SNHL in the high frequencies with thresholds not better than 70 dB HL at 2000-8000 Hz. Children implanted at 6 years to 17 years, 11 months of age should demonstrate a moderate to profound SNHL in the low frequencies, defined by a low-frequency PTA (LFPTA) >40 dB HL at 250, 500, and 1000 Hz with thresholds not better than 65 dB HL at 3000-8000 Hz. Children implanted at 7 months to 5 years, 11 months of age must also demonstrate insufficient functional access to sound with appropriately fitted amplification and aural habilitation. Children who lack the requisite language to complete word recognition testing should demonstrate either a lack of progress or plateau on an accepted scale of auditory skill development (e.g., LittlEARS Auditory Questionnaire (LEAQ), Infant-Toddler Meaningful Auditory Integration Scale (IT-MAIS)). Children with the requisite language to complete word recognition testing should demonstrate a percent correct score ? 40% on a developmentally appropriate test of word recognition (e.g., based on age, cognitive ability, language skills, and clinical judgement). Children implanted at 6 years to 17 years, 11 months of age should demonstrate limited benefit from hearing aids, defined by test scores of 50% correct or less in the ear to be implanted and 60% or less in the non-implant ear on recorded tests of monosyllabic word recognition (e.g., Consonant-Nucleus- Consonant [CNC] Words). Children implanted under 12 months of age should show repeatable behavioral test results that are consistent with objective/electrophysiological test results.¿ MED-EL strongly recommends a hearing aid trial of at least 1-3 months for children without previous hearing aid experience. Risk of ossification or lack of aidable hearing may preclude a hearing aid trial.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Nov 26, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P000025/S134
- Regulatory pathway
- PMA supplement
- Applicant
- Med-El Corp.
- Product code
- MCM
- Decision code
- APPR
- Decision date
- Nov 26, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, cochlear.
- Applicant
- Med-El Corp.
- Product code
- MCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P000025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P000025 · Original PMA
COMBI 40+ COCHLEAR IMPLANT SYSTEM
P000025/S134 received
Application receipt date recorded by FDA.
P000025/S134 · FDA decision
Panel Track
P000025/S137 · Related supplement
MED-EL Cochlear Implant
P000025/S136 · Related supplement
MED-EL Cochlear Implant System
Timeline entries are records held by MedtechLedger for P000025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Med-El Corp. | PMA approval | Aug 20, 2001 | FDA | |
MED-EL Cochlear ImplantP000025/S137 | Med-El Corp. | PMA supplement | Jan 23, 2026 | FDA |
MED-EL Cochlear Implant SystemP000025/S136 | Med-El Corp. | PMA supplement | Oct 9, 2026 | FDA |
Explore the linked device profile
Other records with product code MCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Nucleus 22 Cochlear Implant SystemP840024/S099 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP890027/S067 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 24 Cochlear Implant SystemP970051/S244 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
CLARION MULTI-STRATEGY COCHLEAR IMPLANTP960058/S178 | Advanced Bionics | PMA supplement | Sep 18, 2026 | FDA |
HiResolution Bionic Ear SystemP960058/S177 | Advanced Bionics | PMA supplement | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Med-El Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Furstenweg 77a, Innsbruck, 6020
Sources and methodology
- Original FDA record: P000025/S134
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



